AGIOS PHARMACEUTICALS, INC. Cash and Restricted Cash
AGIOS PHARMACEUTICALS, INC. (AGIO) had Cash and Restricted Cash of $99.65 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-07-30
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $99.65M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $113.60M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $89.13M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $92.71M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $99.65M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $113.60M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $89.13M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $92.71M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $80.87M 10-Q · filed 2026-07-30 |
| 2025-03-31 | $78.96M 10-Q · filed 2026-04-29 |
| 2024-12-31 | $76.25M 10-Q · filed 2026-07-30 |
| 2024-09-30 | $253.73M 10-Q · filed 2025-10-30 |
| 2024-06-30 | $84.52M 10-Q · filed 2025-07-31 |
| 2024-03-31 | $118.76M 10-Q · filed 2025-05-01 |
| 2023-12-31 | $88.20M 10-K · filed 2026-02-12 |
| 2023-09-30 | $64.33M 10-Q · filed 2024-10-31 |
| 2023-06-30 | $84.75M 10-Q · filed 2024-08-01 |
| 2023-03-31 | $104.14M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $139.26M 10-K · filed 2026-02-12 |
| 2022-09-30 | $122.45M 10-Q · filed 2023-11-02 |
| 2022-06-30 | $88.54M 10-Q · filed 2023-08-03 |
| 2022-03-31 | $80.03M 10-Q · filed 2023-05-04 |
| 2021-12-31 | $203.13M 10-K · filed 2025-02-13 |
| 2021-09-30 | $400.22M 10-Q · filed 2022-11-03 |
| 2021-06-30 | $969.12M 10-Q · filed 2022-08-04 |
| 2021-03-31 | $1.89B 10-Q · filed 2022-05-05 |
| 2020-12-31 | $127.44M 10-K · filed 2024-02-15 |
| 2020-09-30 | $104.86M 10-Q · filed 2021-11-03 |
| 2020-06-30 | $295.86M 10-Q · filed 2021-07-29 |
| 2020-03-31 | $89.09M 10-Q · filed 2021-04-29 |
| 2019-12-31 | $80.93M 10-K · filed 2023-02-23 |
| 2019-09-30 | $81.71M 10-Q · filed 2020-11-05 |
| 2019-06-30 | $83.58M 10-Q · filed 2020-07-30 |
| 2019-03-31 | $103.44M 10-Q · filed 2020-04-30 |
| 2018-12-31 | $70.50M 10-K · filed 2022-02-24 |
| 2018-09-30 | $156.48M 10-Q · filed 2019-10-31 |
| 2018-06-30 | $210.32M 10-Q · filed 2019-08-01 |
| 2018-03-31 | $364.47M 10-Q · filed 2019-05-02 |
| 2017-12-31 | $102.72M 10-K · filed 2021-02-25 |
| 2016-12-31 | $160.75M 10-K · filed 2020-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |